Leukemia Clinical Trials in Baltimore

Showing 1601-1620 of 1,652 trials

UCN-01 in Treating Patients With Advanced Cancer

NCT00003289

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of UCN-01 in treating patients with advanced cancer that has not responded to previous treatment.

LeukemiaLymphomaUnspecified Adult Solid Tumor, Protocol Specific

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsStarted Jun 1998

Baltimore, Maryland, United States

COMPLETEDPhase 1< 1 mile

Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer

NCT00064285

RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Drugs used in chemotherapy such as flavopiridol use different ways to stop cancer cells from dividing so they stop growing or die. Combining imatinib mesylate with flavopiridol may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of flavopiridol and imatinib mesylate in treating patients with hematologic cancer.

Leukemia

Virginia Commonwealth University22 participantsStarted Jun 2003

Baltimore, Maryland, United States • Cleveland, Ohio, United States • Philadelphia, Pennsylvania, United States +1 more locations

COMPLETEDPhase 1< 1 mile

Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT00004871

RATIONALE: Azacitidine plus phenylbutyrate may help leukemia cells develop into normal white blood cells. PURPOSE: Phase I trial to study the effectiveness of combining azacitidine and phenylbutyrate in treating patients who have acute myeloid leukemia or myelodysplastic syndrome.

LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsStarted May 2000

Baltimore, Maryland, United States

UCN-01 in Treating Patients With Advanced Cancer

Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer

Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Leukemia Trials in Other Cities

Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML

Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.

BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia

Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia

A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

Carboplatin Plus Cetuximab for Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

Bryostatin 1 and Cytarabine in Treating Patients With Relapsed Acute Myelogenous Leukemia

Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma

Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or Relapsed Leukemia or Lymphoma

Oral NRX 194204 Study in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC

CPG 7909 Injection in Non-Small Cell Lung Cancer

Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML)

Safety Study of XL999 in Adults With Non-Small-Cell Lung Cancer

Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer

Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in the Treatment of Allergic Conjunctivitis

Other Conditions in Baltimore